


RealRate

PHARMACEUTICAL 2019

SPRING PHARMACEUTICAL GROUP INC.

Rank 10 of 371





PHARMACEUTICAL 2019



SPRING PHARMACEUTICAL GROUP INC.

Rank 10 of 371

The relative strengths and weaknesses of SPRING PHARMACEUTICAL GROUP INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SPRING PHARMACEUTICAL GROUP INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 536% points. The greatest weakness of SPRING PHARMACEUTICAL GROUP INC. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 255% points.

The company's Economic Capital Ratio, given in the ranking table, is 325%, being 656% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	30,066
Cost of Goods Sold	39,604
Intangible Assets	11,862
Liabilities, Current	1,983
Liabilities, Non-Current	0
Other Assets	51,417
Other Compr. Net Income	9,115
Other Expenses	9,156
Other Liabilities	0
Other Net Income	0
Property and Equipment	16,793
Research and Development	492
Revenues	64,943
Selling, General and Administrative Expense	4,719

Output Variable	Value in 1000 USD
Assets	110,138
Liabilities	1,983
Expenses	53,971
Stockholders Equity	108,155
Net Income	10,972
Comprehensive Net Income	15,529
Economic Capital Ratio	325%